By Stephen Nakrosis
Shares of biopharmaceutical company Ocular Therapeutix, Inc. are trading higher in the after-hours market on Thursday following the company's release of preliminary second-quarter net product revenue.
The company said it was expecting total net product revenue of about $11.7 million for the second quarter, a better than 600% year-over-year increase.
The company also said net product revenue of Dextenza for the quarter ended June 30 is estimated at $11.1 million, and net product revenue of ReSure Sealant for the quarter estimated at $600,000.
At 5:47 p.m. EDT, the company's shares were trading 5.61% higher at $12.80. Volume at the time topped 70,000 shares.
The company's stock finished the day's regular-trading session with a 4.42% loss at $12.12 a share.
Ocular Therapeutix said it is focused on therapies for diseases and conditions of the eye using its "proprietary bioresorbable hydrogel-based formulation technology."
Write to Stephen Nakrosis at [email protected]